Marvel Biosciences Corp
XTSX:MRVL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.075
0.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CA |
|
Marvel Biosciences Corp
XTSX:MRVL
|
8.1m CAD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
45.7B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.9B CNY |
Loading...
|
|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
28.1B USD |
Loading...
|
|
| DK |
|
Genmab A/S
CSE:GMAB
|
127.8B DKK |
Loading...
|
|
| US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
20.1B USD |
Loading...
|
|
| US |
|
Incyte Corp
NASDAQ:INCY
|
19.9B USD |
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
18.8B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Marvel Biosciences Corp
Glance View
Marvel Biosciences Corp. operates as a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The firm has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.